Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2024)
15 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 22, 2024
Slide 1: April 2024 Proxy Season Update
April 2024 Proxy Season Update
Slide 2: Our Mission, Vision and Values
2 Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our Values Innovation Passion Inclusion Accountability Integrity Urgency Our Vision To be the world’s leading biopharma company that transforms patients’ lives through science.
Slide 3: Advancing our R&D performance
Advancing our R&D performance Harnessing business development to advance value creation and build depth in scientific areas of focus2 Key 2023 Highlights Building on our leadership positions in oncology, hematology and cardiovascular disease and growing our presence in immunology and neuroscience La
Slide 4: Delivering Sustainable Growth and Innovation
4 Delivering Sustainable Growth and Innovation $45.0B Total Revenues in 2023 Strong Commercial Performance $34.3B $3.6B $7.1B In-Line Products* New Product Portfolio** Recent LOE Products*** net sales compared to net sales compared to net sales compared to $33.3B in 2022 $2.0B in 2022 $10.8B in 2022
Slide 5: Progressing our ESG Strategy and Health Equity Initiatives
5 Progressing our ESG Strategy and Health Equity Initiatives INCLUSION & DIVERSITY Executive representation (Executive Director and above): 6.3% 6.5% 47.4% Black/African Hispanic/ Women American (U.S.) Latino (U.S.) (Global) 58% >$1B Clinical trial sites in Global spend with diverse- diverse metro a
Slide 6: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance 6 Board Accountability and Shareholder Rights Regular shareholder engagement Annual election of Directors Majority voting standard for election of Directors Robust Lead Independent Director role Limit on public company board memberships for BMS Directors (4) L
Slide 7: Director Nominees
7 Committees: Audit, CDCG Advisory Partner with Bain & Co. Former Chair of the Board of Blue Cross Blue Shield of Massachusetts, Former Board Member of Kindred Healthcare, National Surgical Hospitals, Value Options, Pediatric Services of American and NeighborCare Director since 2019 Phyllis R. Yale
Slide 8: Overview of 2024 Director Nominees
8 Overview of 2024 Director Nominees Skills, Age & Tenure All Director Nominees possess these qualities: Strategic Thinking Sound Business Judgment Integrity & Ethics Leadership
Slide 9: Continued Commitment to our Compensation Philosophy and Structure
9 Continued Commitment to our Compensation Philosophy and Structure Pay for Performance A substantial proportion of our executives’ pay is variable, at-risk based on our financial and operational results and delivered in the form of equity, supporting alignment over the long term between our executi
Slide 10: Compensation Programs: Supporting Revenue Renewal & Execution of Core Strategy
Compensation Programs: Supporting Revenue Renewal & Execution of Core Strategy 10 * Purple text indicates changes from 2023 to 2024. 2023 Compensation Program Looking Forward: 2024 Compensation Program* Base Salary Annual Incentive (Paid in cash) Allows us to attract and retain talent in a highly co
Slide 11: We Value Your Support at Our 2024 Annual Meeting
We Value Your Support at Our 2024 Annual Meeting 11 FOR Election of Directors FOR Advisory Vote to Approve the Compensation of our Named Executive Officers FOR Ratification of the Appointment of an Independent Registered Public Accounting Firm FOR Approval of an Amendment to our Amended and Restated
Slide 12: We Value Your Support at Our 2024 Annual Meeting (continued)
We Value Your Support at Our 2024 Annual Meeting (continued) 12 Article THIRTEENTH of our Certificate of Incorporation currently allows the company to limit the monetary liability of directors for breach of the fiduciary duty pursuant to and consistent with Section 102(b)(7) of the Delaware General
Slide 13: We Value Your Support at Our 2024 Annual Meeting (continued)
We Value Your Support at Our 2024 Annual Meeting (continued) 13 Shareholder Proposal on Executive Retention of Significant Stock After careful consideration, the Board believes the proposal is not in the best interests of the Company and its shareholders. After thoughtful and rigorous consideration,
Slide 14: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information 14 This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business devel
Slide 15: Bristol Myers Squibb
(lh Bristol Myers Squibb”
Bristol Myers Squibb — Shareholder Meeting (April 2024) on 6ix